Author:
István Greiner
István Greiner
Richter Gedeon Nyrt., Budapest,
Magyarország; Gedeon Richter Plc., Budapest, Hungary
Search for other papers by István Greiner in
Current site
Google Scholar
PubMed
Search for other papers by István Greiner in
Current site
Google Scholar
PubMed
Összefoglaló. A tavalyi évben kitört COVID–19 pandémia jelentős kihívások elé állította a világot. Nem pusztán a kormányok és az egészségügyi rendszerek szembesültek új, békeidőben eddig még nem gyakorolt feladatokkal, de a tudományos világnak is át kellett tekinteni mind a régi, mind a legmodernebb eszközöket ahhoz, hogy a vírus terjedésének, a betegek szenvedéseinek, a tömeges halálozásoknak végre véget lehessen vetni. Habár a járványnak még messze nincsen vége, és egyre újabb és újabb mutánsok ütik fel a fejüket a világ legkülönbözőbb részein, mégis azokat a tanulságokat, melyek már összegyűltek a gyógyszeripar területén, érdemes összefoglalni. Talán még ennél is fontosabb azonban, hogy azokat a hiányokat, amelyeket még be kell pótolni, szintén megemlítsük, hogy ezzel is segítsük az újabb hullámok vagy járványok leküzdését.
Summary. During the last 12 months the most serious issue was the SARS-CoV-2 virus generated pandemia around the world. There is no country which could be more or less intact and a huge amount of resources was sacrificed to rescue people from the fatal outcome of this disease. When it started a year ago or more, there were doubts about its future but later it was realised that this is an epidemic occurring worldwide, crossing international boundaries, and affecting a large number of people. According to the WHO, today the number of confirmed cases is about 157.8 million, confirmed deaths are 3.3 million and 1.2 billion vaccine doses have been administered. These numbers clearly show how important it is to elaborate the reaction of the pharma industry and investigate how to ensure safe drug supply for patients in every country. The topics discussed below are the basic and unique features of the SARS-CoV-2 virus, the pandemia generated by it, and the role of the Hungarian pharma industry, especially Gedeon Richter plc, during this critical period. On one hand the author explains how the spread of virus can be decreased in general and at a production facility like Richter, and on the other hand R&D activity of the Company aiming to cure patients suffering from COVID-19 infection. Consortia including universities, academia and industrial entities made a substantial impact on handling this terrible epidemic. Gedeon Richter plc, the biggest and only independent Hungarian pharma company, in keeping with its roots started small molecule R&D to make favipiravir and remdesivir available to clinics. The latter production is a very difficult one but using its background in chemistry Richter was able to manage all R&D and industrial scale up activities in six months. Moreover, it has filed two patent applications about its new, more feasible and economical process steps justifying its innovative attitude. As a final conclusion it is stated that for the safe supply of necessary medication one critical step is missing from the capabilities of the Hungarian pharma industry, the vaccine R&D and production.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
Baraniuk, C. (2020) Receptors for SARS-CoV-2 Present in Wide Variety of Human Cells. TheScientist, https://www.the-scientist.com/news-opinion/receptors-for-sars-cov-2-present-in-wide-variety-of-human-cells-67496 (Letöltve: 2021. 05. 09.)
-
2
Guo, Q., Xu, M., Guo, S., Zhu, F., Xie, Y., & Shen, J. (2019) The complete synthesis of favipiravir from 2-aminopyrazine. Chemical Papers, Vol. 73, pp. 1043–1051.
-
3
Kacskovics, I. (2021) Magyar fejlesztésű gyógyszer a COVID ellen. https://www.elte.hu/content/magyar-fejlesztesu-gyogyszer-a-covid-ellen.t.22659 (Letöltve: 2021. 05. 09.)
-
4
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., … Lessler, J. (2020) The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann. Int. Med., Vol. 172. No. 9. pp. 577–582.
-
5
Siegel, D., Hui, H. C., Doerffler, E., Clarke, M. O., Chun, K., Zhang, L., … Mackman, R. L. (2017) Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1‑f ][triazin-4-amino] Adenine C‑Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J. Med. Chem., Vol. 60. No. 5. pp. 1648–1661.
-
6
Szekanecz, Z., & Constantin, T. (2020) Citokinvihar Covid-19-fertőzésben. https://mta.hu/tudomany_hirei/citokinvihar-covid-19-fertozesben-110610 (Letöltve: 2021. 05. 09.)
-
7
Szlávik, J. (2021) Szlávik János: egy szuperfertőző maszk nélkül akár 100 embert is megfertőzhet zárt térben. https://budapestkornyeke.hu/szlavik-janos-egy-szuperfertozo-maszk-nelkul-akar-100-embert-is-megfertozhet-zart-terben/ (Letöltve: 2021. 05. 09.)
-
8
Yu, P., Zhu, J., Zhang, Z., & Han, Y. (2020) A Familial Cluster of Infection Associated With the 2019 Novel Coronavirus Indicating Possible Person-to-Person Transmission During the Incubation Period. J. Infect. Dis., Vol. 221 No. 11. pp. 1757–1761.
Editor-in-Chief:
- Tamás NÉMETH
Managing Editor:
- István SABJANICS (Ministry of Interior, Budapest, Hungary)
Editorial Board:
- Valéria CSÉPE (Research Centre for Natural Sciences, Brain Imaging Centre)
- János JÓZSA (Budapest University of Technology and Economics)
- Melinda KOVÁCS (Hungarian University of Agriculture and Life Sciences (MATE))
- Miklós MARÓTH (Eötvös Loránd Research Network)
- Charaf HASSAN (Budapest University of Technology and Economics)
- Zoltán GYŐRI (Hungaricum Committee)
- József HALLER (University of Public Service)
- Attila ASZÓDI (Budapest University of Technology and Economics)
- Zoltán BIRKNER (National Research, Development and Innovation Office)
- Tamás DEZSŐ (Migration Research Institute)
- Imre DOBÁK (University of Public Service)
- András KOLTAY (National Media and Infocommunications Authority)
- Gábor KOVÁCS (University of Public Service)
- József PALLO (University of Public Service)
- Marcell Gyula GÁSPÁR (University of Miskolc)
- Judit MÓGOR (Ministry of Interior National Directorate General for Disaster Management)
- István SABJANICS (Ministry of Interior)
- Péter SZABÓ (Hungarian University of Agriculture and Life Sciences (MATE))
- Miklós SZÓCSKA (Semmelweis University)
Ministry of Interior
Science Strategy and Coordination Department
Address: H-2090 Remeteszőlős, Nagykovácsi út 3.
Phone: (+36 26) 795 906
E-mail: scietsec@bm.gov.hu
DOAJ
| 2020 | |
|---|---|
| CrossRef Documents | 13 |
| CrossRef Cites | 0 |
| CrossRef H-index | 0 |
| Days from submission to acceptance | 247 |
| Days from acceptance to publication | 229 |
| Acceptance Rate | 36% |
| Publication Model | Gold Open Access |
| Submission Fee | none |
| Article Processing Charge | none |
| Scientia et Securitas | |
|---|---|
| Language | Hungarian English |
| Size | A4 |
| Year of Foundation |
2020 |
| Volumes per Year |
1 |
| Issues per Year |
4 |
| Founder | Academic Council of Home Affairs and Association of Hungarian PhD and DLA Candidates |
| Founder's Address |
H-2090 Remeteszőlős, Hungary, Nagykovácsi út 3. H-1055 Budapest, Hungary Falk Miksa utca 1. |
| Publisher | Akadémiai Kiadó |
| Publisher's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. |
| Responsible Publisher |
Chief Executive Officer, Akadémiai Kiadó |
| Applied Licenses |
CC-BY 4.0 CC-BY-NC 4.0 |
| ISSN | ISSN 2732-2688 |
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Apr 2023 | 0 | 6 | 3 |
| May 2023 | 0 | 1 | 1 |
| Jun 2023 | 0 | 5 | 3 |
| Jul 2023 | 0 | 3 | 6 |
| Aug 2023 | 0 | 7 | 3 |
| Sep 2023 | 0 | 7 | 3 |
| Oct 2023 | 0 | 2 | 0 |
Author:
Author:
Author:
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Powered by PubFactory